To say the past year has been rough for investors in Ginkgo Bioworks (NYSE: DNA) would be an understatement of the highest order. As of Aug 14, shares of the synthetic-biology stock were down by 86% ...
Biolase (NASDAQ:BIOL) just reported results for the second quarter of 2024. Biolase reported earnings per share of -8 cents. This was below the analyst estimate for EPS of -7 cents. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results